EDX medical partners with spire healthcare to advance disease diagnostics

Collaboration aims to improve rapid detection and personalised treatments

EDX Medical Group has entered into an agreement with Spire Healthcare Group to advance diagnostic innovations aimed at improving the detection and treatment of major diseases, including cancer, cardiovascular and infectious conditions.

EDX Medical is developing a range of ‘super tests’ for prostate, bowel and testicular cancer. It also provides molecular profiling cancer tests and a platform assessing tumour responses to medicines.

The agreement will explore ways to apply new diagnostic products and patient testing services to Spire Healthcare’s network. Potential initiatives include promoting clinical products, enhancing patient referral pathways and developing joint healthcare propositions based on improved understanding of patient biology and disease risk.

Professor Sir Chris Evans, founder and chief scientific officer of EDX Medical, said: “Spire Healthcare is an outstanding healthcare leader and we at EDX Medical are delighted to sign this agreement which paves the way for us to work together to further improve the delivery of innovative diagnostics and class-leading personalised medicine for patients.”

Dr Mike Hudson, CEO of EDX Medical, added: “We are excited to enter this new initiative with Spire Healthcare which promises to unlock important benefits for Spire’s patients by providing their doctors with early access to advanced clinical diagnostic tools, enabling the delivery of world class personalised medicine.”

Justin Ash, CEO of Spire Healthcare, commented: “We have developed an excellent relationship with EDX Medical and are delighted to collaborate more closely to offer first option on and early access to new, innovative diagnostic products and patient testing services.”